Yidong Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yidong Tan has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Bing Wang
Department of Dermatology, Xinhua Hospital, School of Medicine Shanghai Jiao Tong University Shanghai China
2 shared publications Yan Gu
Department of Dermatology Xinhua Hospital, Shanghai Jiaotong University School of Medicine Shanghai China
2 shared publications- Zhirong Yao
Department of Dermatology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
2 shared publications Chaolan Pan
Department of Dermatology, Xinhua Hospital, School of Medicine Shanghai Jiao Tong University Shanghai China
1 shared publication- Dandan Li
Department of Transfusion Medicine Huashan Hospital Affiliated to Fudan University Shanghai China
1 shared publication Guofang Li
Department of Dermatology Xinhua Hospital, Shanghai Jiaotong University School of Medicine Shanghai China
1 shared publication
Latest Publications
- 17 August 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (8) , e70152
Platelet‐Derived Extracellular Vesicles Alleviate Psoriatic Inflammation via Mitochondrial Transfer to Macrophages
Platelet‐rich plasma (PRP) is a safe, autologous plasma component abundant in cytokines and extracellular vesicles, frequently applied to treat inflammatory disorders. Although PRP demonstrates potential for psoriasis therapy, its underlying mechanism remains insufficiently understood. In this study, various PRP constituents were evaluated in an imiquimod (IMQ)‐induced mouse model of psoriasis. PRP, platelet‐derived extracellular vesicles (PEVs), and platelet‐poor plasma (PPP) were isolated from mice and administered subcutaneously. The data showed that PEVs, rather than PPP, served as the principal anti‐psoriatic factor. Furthermore, RNA sequencing and flow cytometry revealed that PEVs markedly suppressed M1 polarisation of macrophages, thereby mitigating psoriatic‐like inflammation. In vitro, PEVs delivered encapsulated mitochondria to RAW264.7 cells in a concentration‐dependent manner. These functional organelles enhanced oxidative phosphorylation and suppressed glycolysis, driving a metabolic shift favouring an anti‐inflammatory phenotype and attenuating the inflammatory response. In conclusion, PEVs emerge as the primary PRP component responsible for inflammatory suppression in psoriasis. Notably, mitochondria transfer mediated by PEVs underscores a promising therapeutic avenue and provides novel insight into the role of platelet derivatives in inflammatory diseases.
- 17 August 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (8) , e70152
Platelet‐Derived Extracellular Vesicles Alleviate Psoriatic Inflammation via Mitochondrial Transfer to Macrophages
Platelet‐rich plasma (PRP) is a safe, autologous plasma component abundant in cytokines and extracellular vesicles, frequently applied to treat inflammatory disorders. Although PRP demonstrates potential for psoriasis therapy, its underlying mechanism remains insufficiently understood. In this study, various PRP constituents were evaluated in an imiquimod (IMQ)‐induced mouse model of psoriasis. PRP, platelet‐derived extracellular vesicles (PEVs), and platelet‐poor plasma (PPP) were isolated from mice and administered subcutaneously. The data showed that PEVs, rather than PPP, served as the principal anti‐psoriatic factor. Furthermore, RNA sequencing and flow cytometry revealed that PEVs markedly suppressed M1 polarisation of macrophages, thereby mitigating psoriatic‐like inflammation. In vitro, PEVs delivered encapsulated mitochondria to RAW264.7 cells in a concentration‐dependent manner. These functional organelles enhanced oxidative phosphorylation and suppressed glycolysis, driving a metabolic shift favouring an anti‐inflammatory phenotype and attenuating the inflammatory response. In conclusion, PEVs emerge as the primary PRP component responsible for inflammatory suppression in psoriasis. Notably, mitochondria transfer mediated by PEVs underscores a promising therapeutic avenue and provides novel insight into the role of platelet derivatives in inflammatory diseases.
- 10 April 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (4) , e70097
Clinical Responses and Transcriptomic Analysis of Spesolimab in a Girl With Severe Dermatitis, Multiple Allergies and Metabolic Wasting Syndrome
Severe dermatitis, multiple allergies, and metabolic wasting syndrome (SAM) is a rare inherited disorder caused by biallelic loss‐of‐function mutations in the desmoglein‐1 (DSG1) or desmoplakin (DSP) genes. Previous studies have demonstrated that acitretin and systemic biologics targeting IL‐17, IL‐12/IL‐23, and IL‐4 are effective in treating SAM syndrome. We report the case of an 8‐year‐old girl diagnosed with SAM syndrome who suffered from recurrent rash episodes due to infections and achieved remission with a combination therapy of Spesolimab and acitretin. Comprehensive diagnostic workup, including serum inflammatory factor assays, flow cytometry, skin immunohistochemical staining, and skin RNA sequencing (RNA‐seq), revealed elevated IL‐36G levels in SAM syndrome, which may be associated with the pathogenesis of generalised pustular psoriasis (GPP) through shared IL‐36‐mediated mechanisms. This case highlights the therapeutic potential of targeting the IL‐36 pathway in SAM syndrome and supports the use of skin RNA‐seq for personalised selection of anti‐inflammatory biologics in rare dermatological disorders. This report marks the first clinical application of Spesolimab in SAM syndrome, offering a novel therapeutic approach.
- 10 April 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (4) , e70097
Clinical Responses and Transcriptomic Analysis of Spesolimab in a Girl With Severe Dermatitis, Multiple Allergies and Metabolic Wasting Syndrome
Severe dermatitis, multiple allergies, and metabolic wasting syndrome (SAM) is a rare inherited disorder caused by biallelic loss‐of‐function mutations in the desmoglein‐1 (DSG1) or desmoplakin (DSP) genes. Previous studies have demonstrated that acitretin and systemic biologics targeting IL‐17, IL‐12/IL‐23, and IL‐4 are effective in treating SAM syndrome. We report the case of an 8‐year‐old girl diagnosed with SAM syndrome who suffered from recurrent rash episodes due to infections and achieved remission with a combination therapy of Spesolimab and acitretin. Comprehensive diagnostic workup, including serum inflammatory factor assays, flow cytometry, skin immunohistochemical staining, and skin RNA sequencing (RNA‐seq), revealed elevated IL‐36G levels in SAM syndrome, which may be associated with the pathogenesis of generalised pustular psoriasis (GPP) through shared IL‐36‐mediated mechanisms. This case highlights the therapeutic potential of targeting the IL‐36 pathway in SAM syndrome and supports the use of skin RNA‐seq for personalised selection of anti‐inflammatory biologics in rare dermatological disorders. This report marks the first clinical application of Spesolimab in SAM syndrome, offering a novel therapeutic approach.
- 19 July 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 65 (8) , 642-646
Successful treatment of infantile refractory bullous pemphigoid with baricitinib
Infantile bullous pemphigoid (BP) is a rare autoantibody‐mediated skin disorder. We report the effective treatment of a 6‐month‐old infant with BP using baricitinib, a Janus kinase (JAK) inhibitor, after failure with steroids and intravenous immunoglobulin. The patient achieved full remission and discontinued all medications without any relapses. To our knowledge, this is the first case of baricitinib used in an infant with BP.
- 19 July 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 65 (8) , 642-646
Successful treatment of infantile refractory bullous pemphigoid with baricitinib
Infantile bullous pemphigoid (BP) is a rare autoantibody‐mediated skin disorder. We report the effective treatment of a 6‐month‐old infant with BP using baricitinib, a Janus kinase (JAK) inhibitor, after failure with steroids and intravenous immunoglobulin. The patient achieved full remission and discontinued all medications without any relapses. To our knowledge, this is the first case of baricitinib used in an infant with BP.